Glycopyrrolate

# Glycopyrrolate ## Overview - **Classification**: Anticholinergic, muscarinic antagonist. - **Mechanism**: Blocks acetylcholine at muscarinic receptors, reducing glandular secretions (salivary, bronchial), gastric acid, and GI motility. ## Primary Indications 1. **Preoperative Anticholinergic** - Reduces secretions, blocks cardiac vagal reflexes. 2. **Reversal of Neuromuscular Blockade** - Counteracts muscarinic effects of cholinesterase inhibitors. 3. **Chronic Severe Drooling** - Manages excessive saliva production. 4. **Peptic Ulcer Disease** - Adjunctive therapy to reduce gastric acid (oral formulation, less common now). ## Adult Dosing ### Standard Dosing **Preoperative Anticholinergic (Secretions/Vagal Blockade)** - **Dose**: **0.1-0.2 mg** (or **0.004-0.005 mg/kg**) - **Frequency**: Single dose, 30-60 min pre-op - **Route**: IV or IM - **Maximum**: **0.4 mg/dose** **Reversal of Neuromuscular Blockade** - **Dose**: **0.2 mg** for every **1 mg** of neostigmine - **Frequency**: Concurrently with cholinesterase inhibitor - **Route**: IV - **Special Considerations**: Administer as a mixed injection or immediately following the reversal agent. **Chronic Severe Drooling (Oral)** - **Dose**: Initial **1 mg** - **Frequency**: 2-3 times daily - **Route**: Oral - **Maximum**: Titrate up to **2 mg** 3 times daily (total **6 mg/day**) - **Special Considerations**: Start low and titrate slowly (e.g., weekly) to effect/tolerability. **Peptic Ulcer Disease (Oral, Adjunctive)** - **Dose**: **1-2 mg** - **Frequency**: 2-3 times daily - **Route**: Oral - **Maximum**: **8 mg/day** ### Dose Adjustments - **Renal Impairment**: Primarily renally excreted. Use with caution in CrCl <30 mL/min. Consider dose reduction or extended intervals. - **Hepatic Impairment**: Not significantly metabolized by liver. No specific adjustments recommended. - **Elderly Patients**: More sensitive to anticholinergic effects (e.g., confusion, urinary retention). Start with lowest effective dose, titrate slowly. ## Pediatric Dosing ### Neonates (0-28 days) - **Preoperative (IV/IM):** **0.004 mg/kg/dose** - **Frequency**: Single dose - **Maximum**: **0.1 mg/dose** - **Special Notes**: Use with extreme caution. Increased risk of heat stroke due to immature thermoregulatory system. ### Infants (1-12 months) - **Preoperative (IV/IM):** **0.004-0.005 mg/kg/dose** - **Frequency**: Single dose - **Maximum**: **0.1 mg/dose** - **Chronic Drooling (Oral, off-label <3 yrs):** Initial **0.02 mg/kg/dose** 3 times daily. - **Chronic Drooling Maximum**: May titrate to **0.05 mg/kg/dose** 3 times daily. ### Children (1-12 years) - **Preoperative (IV/IM):** **0.004-0.005 mg/kg/dose** - **Frequency**: Single dose - **Maximum**: **0.1 mg/dose** - **Reversal of Neuromuscular Blockade (IV):** **0.2 mg** for every **1 mg** of neostigmine. - **Chronic Drooling (Oral):** Initial **0.02 mg/kg/dose** 3 times daily. - **Chronic Drooling Maximum**: Titrate weekly up to **0.05 mg/kg/dose** 3 times daily OR **1.6 mg/m²** 3 times daily. Max **1.5-3 mg/dose**. ### Adolescents (13-18 years) - **Dose**: Generally follow adult dosing guidelines. - **Maximum**: Adult maximum doses apply. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to glycopyrrolate. - **Absolute**: Glaucoma (angle-closure). - **Absolute**: Obstructive uropathy, GI obstruction, severe ulcerative colitis, toxic megacolon. - **Absolute**: Myasthenia gravis (unless used to counteract cholinesterase inhibitors). - **Relative**: Tachycardia, acute hemorrhage, hyperthyroidism. ### Common Adverse Effects - **Very Common (>10%)**: Dry mouth, constipation, urinary retention, blurred vision. - **Common (1-10%)**: Tachycardia, palpitations, decreased sweating (anhydrosis), drowsiness, headache. - **Serious but Rare**: Anaphylaxis, paradoxical bradycardia (very rare), heat stroke (especially in children/elderly). ### Key Drug Interactions - **Other Anticholinergics (e.g., TCAs, antihistamines)**: Potentiates anticholinergic effects. Monitor for increased dry mouth, urinary retention, constipation. - **Potassium Chloride (oral)**: Increased risk of GI lesions due to decreased GI motility. Avoid concomitant use. - **Antacids**: May reduce oral glycopyrrolate absorption. Separate administration by at least 2 hours. ## Monitoring & Follow-up - **Before Treatment**: Baseline heart rate, blood pressure, assess for contraindications (e.g., history of glaucoma, urinary retention). - **During Treatment**: Monitor for anticholinergic side effects (dry mouth, constipation, urinary retention, blurred vision, tachycardia). - **Clinical Signs**: Observe for changes in heart rate, GI function, urinary output, mental status. Monitor body temperature, especially in hot environments or febrile patients. ## Clinical Pearls - 💡 **Tip 1**: Administer oral glycopyrrolate at least 1 hour before or 2 hours after meals for optimal absorption. - 💡 **Tip 2**: For chronic drooling, emphasize slow titration to manage anticholinergic side effects effectively. - 💡 **Tip 3**: Counsel patients on the risk of heat stroke, particularly in warm environments or during physical activity, due to reduced sweating. - 💡 **Tip 4**: IV glycopyrrolate typically has a faster onset and shorter duration than atropine for anti-sialagogue effects. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.